We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 12

IP challenges for the personalised medicines industry - gene claims (part 1)

  • Barker Brettell LLP
  • -
  • European Union, United Kingdom, USA
  • -
  • May 9 2013

When you go to the doctor you expect to be asked a lot of questions about your symptoms and your lifestyle, as the doctor builds up a clinical

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Overview of patent-statutory subject matter in biotechnology

  • CCPIT Patent & Trademark Law Office
  • -
  • China, European Union, Japan, USA
  • -
  • April 8 2013

With the advent of biotechnology, the human community stands on the threshold of an extraordinary revolution having profound

Patent claims for ‘personalised medicines’

  • Mewburn Ellis LLP
  • -
  • European Union, USA
  • -
  • February 7 2013

As previously reported the US Supreme Court, in Mayo v. Prometheus, recently invalidated Prometheus's diagnostic claims - directed to a method of

European Commission ups the cost of paying for delay

  • King & Wood Mallesons
  • -
  • Australia, European Union, USA
  • -
  • August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram

Legal implications and business considerations for technologies involving human embryonic stem cells in Europe and U.S.

  • Morrison & Foerster LLP
  • -
  • European Union, USA
  • -
  • June 27 2012

The future may be getting brighter for stem cell researchers in the United States as restrictions for funding of stem cell research have been loosened, but efforts to commercialize stem cell technologies have faced a new hurdle with a recent decision by a European court regarding the patentability of human embryonic stem cells

Life sciences & law current issues 201213

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union, USA
  • -
  • June 18 2012

Each stage of the life cycle of a company or a product presents challenges that demand the expertise and resources of a strong legal partner

Navigating the evolving regulation and commercialization of stem cell research

  • McDermott Will & Emery
  • -
  • European Union, USA
  • -
  • March 22 2012

Interested parties that can successfully navigate the evolving regulation of stem cell research stand to gain significant scientific and commercial advantage

Antitrust, competition and economic regulation client quarterly newsletter

  • Hogan Lovells
  • -
  • China, European Union, Greece, USA
  • -
  • January 24 2012

A public company CEO recently consented to a federal district court order requiring him to pay a $500,000 civil penalty for violating the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”

Tribunals and the Court of Justice of the European Union consider whether sick workers can carry over statutory holiday andor holiday pay

  • Jones Day
  • -
  • European Union, United Kingdom, USA
  • -
  • January 3 2012

In Adams and another v Harwich International Port Ltd, an employment tribunal held that sick workers may carry over their statutory annual leave entitlement until the next leave year (but not necessarily beyond) if unable or unwilling to take it due to sickness or if so required by the employer

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy